한글목차

본 보고서에서는 헌팅턴병 임상시험에 대해 조사 분석하여 각국의 임상시험 수와 평균 등록자 수, 임상시험 중인 주요 약물에 대한 정보 등을 제공합니다.

목차

표 리스트

도표 리스트

• 보고서 가이던스
• GlobalData의 임상시험 보고서 범위
• 임상시험 건수 : 지역별
• 임상시험 건수와 평균 등록수 : 국가별
• 아시아태평양 임상시험에 기여하고 있는 주요 5개국
• 유럽의 임상시험에 기여하고 있는 주요 5개국
• 북미의 임상시험에 기여하고 있는 주요 국가
• 중동 및 아프리카의 임상시험에 기여하고 있는 주요 국가
• 중남미의 임상시험에 기여하고 있는 주요 국가
• G7 국가의 임상시험 : 중추신경계 임상시험 전체 대비 헌팅턴병 임상시험 비율
• G7 국가의 임상시험 : 단계별
• G7 국가의 임상시험 : 시험 현황별
• E7 국가의 임상시험 : 중추신경계 임상시험 전체 대비 헌팅턴병 임상시험 비율
• E7 국가의 임상시험 : 단계별
• E7 국가의 임상시험 : 시험 상황별
• 임상시험 : 단계별
• 진행 중인 임상시험 : 단계별
• 임상시험 : 시험 현황별
• 임상시험 : 엔드포인트 현황별
• 일정기간에 걸쳐 채택된 피험자
• 임상시험 : 스폰서 유형별
• 저명한 스폰서
• 헌팅턴병 치료 임상시험에 참가하고 있는 주요 기업
• 저명한 약제
• 헌팅턴병에 관한 최신 임상시험 뉴스
• 2025년 9월 15일 : SOM Biotech, 헌팅턴병 치료제 SOM3355 유럽 희귀의약품 지정에 대해 EMA COMP 긍정적 견해를 취득
• 2025년 9월 5일 : Nature Medicine, 초기 단계 헌팅턴병 Pridopidine 단계 3 임상시험 데이터를 발표해, 임상 진행에 대한 영향을 강조
• 2025년 7월 8일 : MMJ International, 희소 신경질환에 대한 첫 식물 유래약으로 의료용 대마를 재정의
• 2025년 6월 27일 : Neurocrine Biosciences, HD 치료제 INGREZZA 캡슐에 의한 질병 부하 대폭적인 경감을 나타내는 KINECT-HD 시험 신데이터를 발표
• 임상시험 프로파일 현황

부록

영문목차

GlobalData's clinical trial report, "Huntington Disease - Global Clinical Trials Review, 2025" provides an overview of Huntington Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Huntington Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

• Report Guidance
• GlobalData Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Countries Contributing to Clinical Trials in Middle East and Africa
• Top Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Huntington Disease to Central Nervous System Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Huntington Disease to Central Nervous System Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Huntington Disease Therapeutics Clinical Trials
• Prominent Drugs
• Latest Clinical Trials News on Huntington Disease
• Sep 15, 2025: SOM Biotech Receives Positive EMA COMP Opinion on European Orphan Drug Designation for SOM3355 for Treatment of Huntington's Disease
• Sep 05, 2025: Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington's Disease, Highlighting Impact on Clinical Progression
• Jul 08, 2025: MMJ International Redefines Medical Cannabis with First Plant-Based Drug for a Rare Neurological Disease
• Jun 27, 2025: Neurocrine Biosciences Presents New Data From KINECT-HD Study Demonstrating Significant Reduction in Disease Burden With INGREZZA Capsules for HD
• Clinical Trial Profile Snapshots

Appendix

• Abbreviations
• Definitions
• Research Methodology
• Secondary Research
• About GlobalData
• Contact Us
• Source